Sarepta Shares Slide After Steep Drop in Elevidys Sales
Sarepta Therapeutics saw its stock tumble in premarket trading after reporting a sharp decrease in first-quarter revenue from its gene therapy Elevidys. The company attributed the decline in sales volume to an updated label that limits treatment to patients who can walk - a change issued by the FDA following safety concerns and patient deaths. Over…